Company:  EYEPOINT PHARMACEUTICALS, ... (EYPT)
Form Type:  8-K
Filing Date:  5/5/2021 
CIK:  0001314102 
Address:  480 PLEASANT STREET
SUITE B300
 
City, State, Zip:  WATERTOWN, Massachusetts 02472 
Telephone:  617-926-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$11.11  
Change: 
0.02 (0.18%)  
Trade Time: 
Aug 12  
Market Cap: 
$378.26M
Trade EYPT now with 

© 2022  
Description of Business
We are a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. Our pipeline leverages our proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month anti-VEGF treatment initially targeting wet age-related macular degeneration ("wet AMD"), the leading cause of vision loss among people 50 years of age and older in the United States. We also have two commercial products: YUTIQ®, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, a single dose treatment for postoperative inflammation following ocular surgery. We are also advancing YUTIQ 50, a potential six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness under a supplemental New Drug Application ("sNDA") strategy.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1
    INCOME STATEMENT
    BALANCE SHEET